Author: James Love
Technology transfer obligations in legislation proposed in the United States (in the 117th Congress)
I’m in a two day meeting in Geneva on new approaches to affordable monoclonal antibodies (mAbs), and it made me think of a provision found in some bills that have been proposed or introduced in the U.S. Congress to force… Continue Reading
The Trouble with the WIPO Broadcast Treaty
KEI has shared this analysis of the WIPO negotiations on a broadcasting treaty with negotiators. WIPO-Broadcast-Treaty-Analysis-28Feb2023 Brief update 1: The WIPO negotiations on a broadcasting treaty began in 1997. This week, the broadcasters hope to finally get an SCCR node… Continue Reading
US government files statement of Interest in Arbutus v Moderna case, testing scope of 28 USC 1498(a) government use of patents for acquisition and distribution of COVID 19 vaccines
On February 14, 2023, USDOJ filed a Statement of Interest of the United States, in the patent dispute between Arbutus Biopharma, Genevant Sciences, and Moderna. A copy of the filing is here: arbutus.moderna.USG.statementofinterest This is an important, and while not… Continue Reading
WHO releases the zero draft of the pandemic treaty, and it’s a very good start
WHO-zero-draft-pandemic-treaty-1Feb2023 There is much to like in this draft on topics such as intellectual property rights, transparency, benefit sharing and equity. Easy to see why big drug companies have been alarmed at the direction of the WHO work on this.… Continue Reading
KEI comments to USTR regarding the 2023 Special 301 process
USTR-Special301-2023-KEI-coments KEI comments on the 2023 USTR Special 301 Review Comments provided by James Love, on behalf of Knowledge Ecology International 110 Maryland Avenue, NE, Washington, DC 20002 Telephone: +1.202.332.2670 James.Love@KEIOnline.Org In response to Federal Register Notice: Docket Number USTR-2022-0016… Continue Reading
NIH responds to Sachs/Love letter on the Xtandi Bayh-Dole safeguards petition, to say, still reviewing
NIH has sent a letter, dated Dec 1, to Robert Sachs and Clare Love, regarding the longstanding petition to HHS to use the federal government’s rights in the patented inventions for enzalutamide, marketed by Astellas in the USA at prices 3 to… Continue Reading
Letter from 19 groups asking HHS to take action on the request that HHS use the federal government rights in patents on the prostate drug enzalutamide, marketed by Astellas under the brand name Xtandi.
Attached is a letter from 19 groups asking HHS Secretary Xavier Becerra to take action on the request that HHS use the federal government rights in patents on the prostate drug enzalutamide, marketed by Astellas under the brand name Xtandi.… Continue Reading
Letter to Secretary of HHS Xavier Becerra regarding Xtandi march-in case from Robert Sachs and Clare Love
SecBecerra-18Nov2022-Sachs-Love-Xtandi November 18, 2022 Xavier Becerra Secretary Department of Health & Human Services Washington, DC Via Email: xavier.becerra@hhs.gov Dear Secretary Becerra: Today marks the one-year anniversary since the undersigned prostate cancer patients petitioned the Department of Health & Human Services… Continue Reading